← Back
Data updated: Mar 29, 2026
TRIS PHARMA INC
MetabolicCardiovascularGastroenterology
Generics
TRIS PHARMA INC is a generic drug manufacturer focused on Metabolic, Cardiovascular, Gastroenterology. Key products include DYANAVEL XR 20.
2009
Since
28
Drugs
-
Trials
428
Approved (2yr)
Key Drugs
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Recent Activity
DEFLAZACORT 2026-01-27
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
SEC Filings
Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Metabolic 77%
4 drugs
Cardiovascular 19%
1 drugs
Gastroenterology 3%
0 drugs Phase 1: 1
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Active (14)
Discontinued (13)
HYDROCODONE BITARTRATE AND ACETAMINOPHEN MORPHINE SULFATE POTASSIUM CHLORIDE TUZISTRA XR CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF RISPERIDONE THEOPHYLLINE HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE DEXMETHYLPHENIDATE HYDROCHLORIDE HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE CYPROHEPTADINE HYDROCHLORIDE
Company Info
- First Approval
- 2009-08-31
- Latest
- 2025-12-22
- Applications
- 28